our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.
Company profile
Ticker
ERAS
Exchange
Website
CEO
Jonathan E. Lim
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
831217027
ERAS stock data
Latest filings (excl ownership)
8-K
Erasca Announces $45 Million Oversubscribed Private Placement Financing
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
27 Mar 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Other Events
11 Dec 23
8-K
Other Events
28 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
9 Nov 23
8-K
Other Events
29 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Latest ownership filings
144
Notice of proposed sale of securities
15 Apr 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
City Hill, LLC
13 Feb 24
4
Jonathan E Lim
7 Feb 24
4
David M. Chacko
7 Feb 24
4
Ebun Garner
7 Feb 24
4
Shannon Morris
7 Feb 24
SC 13D/A
Cormorant Asset Management, LP
30 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 113.27 mm | 113.27 mm | 113.27 mm | 113.27 mm | 113.27 mm | 113.27 mm |
Cash burn (monthly) | 8.64 mm | 8.87 mm | 11.55 mm | 20.48 mm | 8.04 mm | 8.57 mm |
Cash used (since last report) | 57.88 mm | 59.39 mm | 77.38 mm | 137.16 mm | 53.85 mm | 57.38 mm |
Cash remaining | 55.39 mm | 53.88 mm | 35.89 mm | -23.89 mm | 59.42 mm | 55.89 mm |
Runway (months of cash) | 6.4 | 6.1 | 3.1 | -1.2 | 7.4 | 6.5 |
Institutional ownership, Q3 2023
70.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 112 |
Opened positions | 10 |
Closed positions | 11 |
Increased positions | 48 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 129.93 bn |
Total shares | 106.54 mm |
Total puts | 600.00 |
Total calls | 400.00 |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Novartis Pharma | 12.31 mm | $69.91 mm |
City Hill | 11.90 mm | $0.00 |
Arch Venture | 11.06 mm | $21.78 bn |
ARCH Venture Fund X | 11.06 mm | $172.25 mm |
Cormorant Asset Management | 10.81 mm | $21.30 bn |
Armistice Capital | 8.36 mm | $16.46 bn |
BLK Blackrock | 7.03 mm | $13.84 bn |
Vanguard | 5.12 mm | $10.08 bn |
Artal | 4.72 mm | $9.30 mm |
Partner Fund Management | 3.93 mm | $7.74 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Feb 24 | Shannon Morris | Stock Option Common Stock | Grant | Acquire A | No | No | 1.7 | 535,800 | 910.86 k | 535,800 |
5 Feb 24 | David M. Chacko | Stock Option Common Stock | Grant | Acquire A | No | No | 1.7 | 600,000 | 1.02 mm | 600,000 |
5 Feb 24 | Ebun Garner | Stock Option Common Stock | Grant | Acquire A | No | No | 1.7 | 480,000 | 816.00 k | 480,000 |
5 Feb 24 | Jonathan E Lim | Stock Option Common Stock | Grant | Acquire A | No | No | 1.7 | 1,500,000 | 2.55 mm | 1,500,000 |
1 Jan 24 | Bristol James Arthur | Stock Option Common Stock | Grant | Acquire A | No | No | 2.13 | 62,747 | 133.65 k | 62,747 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Apr 24
Goldman Sachs Maintains Buy on Erasca, Raises Price Target to $7
2 Apr 24
HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $8 Price Target
28 Mar 24
Reported Earlier, Erasca Announced $45M Oversubscribed Private Placement Financing
28 Mar 24
Erasca Q4 EPS $(0.20) Beats $(0.21) Estimate
27 Mar 24